ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Kineta Announces First Participant Dosed in KCP506 Trial for Chronic Pain americanpharmaceuticalreview
December 17, 2020Kineta, through its subsidiary Kineta Chronic Pain LLC, announced the first participant has been successfully dosed in a Phase 1 clinical trial of KCP506, an investigational, first-in-class α9/α10 nicotinic acetylcholine receptor (nAChR) antagonist in ... -
Kineta Receives Regulatory Approval for Initiation of KCP506 Trial americanpharmaceuticalreview
August 18, 2020Kineta announced the Clinical Trial Application (CTA) approval in the Netherlands for initiation of a first in-human clinical trial of KCP506. KCP506 is a first-in-class α9α10 nicotinic acetylcholine receptor (nAChR) antagonist in development for the ...
Pharma Sources Insight January 2025
